Roche, Trimeris withdraw application for Fuzeon injection device

10/3/2007 | News & Observer (Raleigh, N.C.), The · Forbes

Roche Holding subsidiary Hoffmann-La Roche and Trimeris said they are withdrawing their FDA application to market the Biojector 2000 needle-free injection device in combination with HIV drug Fuzeon, following a comprehensive evaluation of a clinical trial and a delay in getting regulatory approval. The companies believe the device isn't an ideal substitute for the delivery of the drug among "all treatment-experienced patients" despite its potential benefits, a Roche official said.

View Full Article in:

News & Observer (Raleigh, N.C.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN